SAG
JAZZ icon

SageView Advisory Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

SageView Advisory Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-69
Closed -$11.7K – 1524
2025
Q4 		$11.7K Buy
+69
New +$10.6K ﹤0.01% 1656

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

SageView Advisory Group's JAZZ Position: Q1 2026 in Review

SageView Advisory Group sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 69 shares — an estimated $11.7K sold.

SageView Advisory Group first reported a position in JAZZ in Q4 2025 and held it in 1 quarter. The position peaked at $11.7K in Q4 2025. 576 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • SageView Advisory Group reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 69 Jazz Pharmaceuticals shares in Q1 2026, an estimated $11.7K.
  • SageView Advisory Group first reported a position in Jazz Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Jazz Pharmaceuticals position peaked at $11.7K in Q4 2025.
  • 576 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.